These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 23633457)

  • 1. Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.
    Linehan WM; Rouault TA
    Clin Cancer Res; 2013 Jul; 19(13):3345-52. PubMed ID: 23633457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.
    Tong WH; Sourbier C; Kovtunovych G; Jeong SY; Vira M; Ghosh M; Romero VV; Sougrat R; Vaulont S; Viollet B; Kim YS; Lee S; Trepel J; Srinivasan R; Bratslavsky G; Yang Y; Linehan WM; Rouault TA
    Cancer Cell; 2011 Sep; 20(3):315-27. PubMed ID: 21907923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
    Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
    Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma.
    Yang Y; Lane AN; Ricketts CJ; Sourbier C; Wei MH; Shuch B; Pike L; Wu M; Rouault TA; Boros LG; Fan TW; Linehan WM
    PLoS One; 2013; 8(8):e72179. PubMed ID: 23967283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
    Sourbier C; Ricketts CJ; Liao PJ; Matsumoto S; Wei D; Lang M; Railkar R; Yang Y; Wei MH; Agarwal P; Krishna M; Mitchell JB; Trepel JB; Neckers L; Linehan WM
    Sci Rep; 2019 Dec; 9(1):18409. PubMed ID: 31804603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes.
    Podkalicka P; Mucha O; Kruczek S; Biela A; Andrysiak K; Stępniewski J; Mikulski M; Gałęzowski M; Sitarz K; Brzózka K; Józkowicz A; Dulak J; Łoboda A
    Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31963199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
    Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
    Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
    Ooi A
    Semin Cancer Biol; 2020 Apr; 61():158-166. PubMed ID: 31689495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism.
    Bardella C; Olivero M; Lorenzato A; Geuna M; Adam J; O'Flaherty L; Rustin P; Tomlinson I; Pollard PJ; Di Renzo MF
    Mol Cell Biol; 2012 Aug; 32(15):3081-94. PubMed ID: 22645311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase.
    Frezza C; Zheng L; Folger O; Rajagopalan KN; MacKenzie ED; Jerby L; Micaroni M; Chaneton B; Adam J; Hedley A; Kalna G; Tomlinson IP; Pollard PJ; Watson DG; Deberardinis RJ; Shlomi T; Ruppin E; Gottlieb E
    Nature; 2011 Aug; 477(7363):225-8. PubMed ID: 21849978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC).
    Chan E; Rabban JT; Mak J; Zaloudek C; Garg K
    Am J Surg Pathol; 2019 Sep; 43(9):1170-1179. PubMed ID: 31162287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fumarate hydratase as a therapeutic target in renal cancer.
    Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
    Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer.
    Shuch B; Li S; Risch H; Bindra RS; McGillivray PD; Gerstein M
    Cancer; 2020 Aug; 126(16):3657-3666. PubMed ID: 32413184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
    Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
    BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.
    Xie H; Valera VA; Merino MJ; Amato AM; Signoretti S; Linehan WM; Sukhatme VP; Seth P
    Mol Cancer Ther; 2009 Mar; 8(3):626-35. PubMed ID: 19276158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
    Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
    Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings.
    Harrison WJ; Andrici J; Maclean F; Madadi-Ghahan R; Farzin M; Sioson L; Toon CW; Clarkson A; Watson N; Pickett J; Field M; Crook A; Tucker K; Goodwin A; Anderson L; Srinivasan B; Grossmann P; Martinek P; Ondič O; Hes O; Trpkov K; Clifton-Bligh RJ; Dwight T; Gill AJ
    Am J Surg Pathol; 2016 May; 40(5):599-607. PubMed ID: 26574848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fumarate Hydratase-Deficient Leiomyoma of the Uterine Corpus: Comparative Morphologic Analysis of Protein-Deficient Tumors With and Without Pathogenic Germline Fumarate Hydratase Gene Mutations.
    Shi W; Liu Y; Aisagbonhi O; Roma AA; Hasteh F; Zare SY; Fadare O
    Int J Surg Pathol; 2024 Apr; 32(2):340-355. PubMed ID: 37312573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
    Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
    Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
    Bayley JP; Launonen V; Tomlinson IP
    BMC Med Genet; 2008 Mar; 9():20. PubMed ID: 18366737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.